All In Biotech

Drug Trial Radar · NCT05532722

ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

A Study of ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Sep 28, 2022

Primary completion

Aug 28, 2025

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Abcuro, Inc.Industry
Sponsor type
Industry
First posted
Sep 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

Conditions

  • T-cell Large Granular Lymphocytic Leukemia

Interventions

  • ABC008Drug

    Given subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0Time frame: Through Study Completion an average of 48 weeks

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of Southern California

    Los Angeles, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.